Here, we compared the impact of the difference in immunogenicity of the TUBO tumour in non-isogenic WT and isogenic transgenic BALB/c-NeuT mice on the therapeutic efficacy of anti-neu mAb therapy. This evidence concerns the gene ERBB2 and neoplasm.